Entries by Karen Hynes

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

Caution: The iLet Bionic Pancreas is an investigational device limited by Federal law to investigational use. Not available for sale. CONCORD, Mass., January 4, 2023: Beta Bionics, Inc. — a clinical-stage medical technology company —announced the appointment of Steven Russell, MD, PhD, to the role of Chief Medical Officer as the company prepares for commercial […]

Beta Bionics Appoints Sean Saint as CEO and Board Member

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not available for sale.  CONCORD, Mass., August 15, 2022 (GLOBE NEWSWIRE) — Beta Bionics, Inc. — a clinical-stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — today […]

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) included a more diverse population of participants with type 1 diabetes (T1D) than previous pivotal studies of other AID systems with respect to minority […]

Beta Bionics Appoints Gilad Glick to the Board of Directors and Veena Rao, Ph.D. as Chief Commercial Officer

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Gilad Glick, former Chief Executive Officer, Itamar Medical, appointed to Beta Bionics’ Board of Directors Veena Rao, Ph.D., Vice President of Business Development and interim Chief Commercial Officer, appointed Chief Commercial Officer CONCORD, […]

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.   The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.  The study population — 440 adults and children 6 years and […]

Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Steven J. Russell will present the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) on Saturday, April 30, […]

Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. ·       Dr. Ed Damiano, President & CEO of Beta Bionics, is now assuming the role of Founder and Executive Chair ·       Martha Goldberg Aronson, Board Chair, is now serving as interim CEO […]

Beta Bionics Announces Closing of $57 Million Series C Financing

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The financing round was co-led by existing Series B and B-2 investors Soleus Capital, Perceptive Advisors, Farallon Capital Management, L.L.C., RTW Investments, LP, and Eventide Asset Management New investor Pura Vida Investments participated […]

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial

The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The iLet® Bionic Pancreas is a pocket-sized, wearable investigational medical device that is designed to autonomously determine and deliver insulin and/or glucagon doses to control blood-glucose levels in people with diabetes and other […]

Beta Bionics is a public benefit corporation.

We are committed to balancing purpose with profit and giving back to society as we fulfill our public benefit mission.

Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at www.betabionics.com/resouces/user-guides, or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to www.betabionics.com/resources/safety. DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.

Medical Disclaimer – This website is for information only and is not a substitute for medical advice and/or services from a healthcare provider. All personal health care decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs.

Copyright © 2023 Beta Bionics | Privacy Policy | Terms of Use | Cookies